An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Jayakrishnan, Bindu ^a   Hoke, David E ^a   Langendorf, Christopher G ^a   Buckle, Ashley M ^a   Rowley, Merrill J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE 67; GLUTAMATE DECARBOXYLASE 67 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GLUTAMATE DECARBOXYLASE 2;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIABETES MELLITUS; HUMAN; IMMUNOBLOTTING; IMMUNOGENICITY; RADIOIMMUNOPRECIPITATION; ENZYMOLOGY; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CROSS REACTIONS; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOBLOTTING; RADIOIMMUNOPRECIPITATION ASSAY;

EID: 79954497707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018411     Document Type: Article

References (35)

1. Lernmark A, (1996) Glutamic acid decarboxylase-gene to antigen to disease. J Intern Med 240: 259-277.
2. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, et al. (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48: 150-157.
3. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P, (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322: 1555-1560.
4. Solimena M, De Camilli P, (1991) Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 14: 452-457.
5. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, et al. (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151-156.
6. Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, et al. (2006) Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 81: 1207-1214.
7. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, et al. (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131: 2553-2563.
8. Petersen JS, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, et al. (1994) Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43: 459-467.
9. Bingley PJ, (2010) Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 95: 25-33.
10. Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, et al. (1993) Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes 42: 631-636.
11. Fenalti G, Rowley MJ, (2008) GAD65 as a prototypic autoantigen. J Autoimmun 31: 228-232.
12. Battaglioli G, Liu H, Martin DL, (2003) Kinetic differences between the isoforms of glutamate decarboxylase: implications for the regulation of GABA synthesis. J Neurochem 86: 879-887.
13. Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, et al. (2007) GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol 14: 280-286.
14. Fenalti G, Hampe CS, Arafat Y, Law RH, Banga JP, et al. (2008) COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 57: 1293-1301.
15. Arafat Y, Fenalti G, Whisstock JC, Mackay IR, Garcia de la Banda M, et al. (2009) Structural determinants of GAD antigenicity. Mol Immunol 47: 493-505.
16. Fenalti G, Buckle AM, (2010) Structural biology of the GAD autoantigen. Autoimmun Rev 9: 148-152.
17. Seissler J, Bieg S, Yassin N, Mauch L, Northemann W, et al. (1994) Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II. Autoimmunity 19: 231-238.
18. Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C, et al. (1993) Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 91: 2084-2090.
19. Mueller PW, Bingley PJ, Bonifacio E, Steinberg KK, Sampson EJ, (2002) Predicting type 1 diabetes using autoantibodies: the latest results from the diabetes autoantibody standardization program. Diabetes Technol Ther 4: 397-400.
20. Bingley PJ, Bonifacio E, Mueller PW, (2003) Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52: 1128-1136.
21. Chang YC, Gottlieb DI, (1988) Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. J Neurosci 8: 2123-2130.
22. Gottlieb DI, Chang YC, Schwob JE, (1986) Monoclonal antibodies to glutamic acid decarboxylase. Proc Natl Acad Sci U S A 83: 8808-8812.
23. Papakonstantinou T, Law RH, Gardiner P, Rowley MJ, Mackay IR, (2000) Comparative expression and purification of human glutamic acid decarboxylase from Saccharomyces cerevisiae and Pichia pastoris. Enzyme Microb Technol 26: 645-652.
24. Law RH, Rowley MJ, Mackay IR, Corner B, (1998) Expression in Saccharomyces cerevisiae of antigenically and enzymatically active recombinant glutamic acid decarboxylase. J Biotechnol 61: 57-68.
25. Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, et al. (2007) GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 56: 1527-1533.
26. O'Connor KH, Banga JP, Darmanin C, El-Kabbani O, Mackay IR, et al. (2006) Characterisation of an autoreactive conformational epitope on GAD65 recognised by the human monoclonal antibody b78 using a combination of phage display, in vitro mutagenesis and molecular modelling. J Autoimmun 26: 172-181.
27. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, et al. (2005) Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 175: 7755-7762.
28. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P, (1993) Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 178: 2097-2106.
29. Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, et al. (2006) Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab). Exp Neurol 202: 514-518.
30. Richter W, Shi Y, Baekkeskov S, (1993) Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci U S A 90: 2832-2836.
31. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, et al. (1994) Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 180: 595-606.
32. Ziegler B, Schlosser M, Luhder F, Strebelow M, Augstein P, et al. (1996) Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome. Acta Diabetol 33: 225-231.
33. Al-Bukhari TA, Radford PM, Bouras G, Davenport C, Trigwell SM, et al. (2002) Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis. Clin Exp Immunol 130: 131-139.
34. Piquer S, Belloni C, Lampasona V, Bazzigaluppi E, Vianello M, et al. (2005) Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol 117: 31-35.
35. Schwartz HL, Chandonia JM, Kash SF, Kanaani J, Tunnell E, et al. (1999) High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 287: 983-999.